Should β-catenin perform such a role in AML cells, it may well explain why pharmacological attempts to disrupt β-catenin interaction with transcriptional partners (e.g. TCF/LEF) has not yielded the clinical success expected, because β-catenin may also influence post-transcriptional expression. This evidence concerns the gene HNF4A and acute myeloid leukemia.